David P. Byar
#140,509
Most Influential Person Now
David P. Byar's AcademicInfluence.com Rankings
David P. Byarmathematics Degrees
Mathematics
#6643
World Rank
#9161
Historical Rank
Statistics
#651
World Rank
#735
Historical Rank
Download Badge
Mathematics
David P. Byar's Degrees
- PhD Biostatistics University of North Carolina at Chapel Hill
- Masters Biostatistics University of North Carolina at Chapel Hill
- Bachelors Mathematics University of North Carolina at Chapel Hill
Similar Degrees You Can Earn
Why Is David P. Byar Influential?
(Suggest an Edit or Addition)David P. Byar's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. (1989) (3091)
- Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. (1980) (1601)
- Estimating the population attributable risk for multiple risk factors using case-control data. (1985) (1225)
- The ecological fallacy. (1988) (842)
- The veterans administration cooperative urological research group's studies of cancer of the prostate (1973) (586)
- A prognostic index for thyroid carcinoma. A study of the E.O.R.T.C. Thyroid Cancer Cooperative Group. (1979) (543)
- Carcinoma of the prostate: Prognostic evaluation of certain pathologic features in 208 radical prostatectomies (1972) (445)
- Randomized clinical trials. Perspectives on some recent ideas. (1976) (424)
- Comparisons of carmustine, procarbazine, and high-dose methylprednisolone as additions to surgery and radiotherapy for the treatment of malignant glioma. (1983) (419)
- Evaluation of Response-Time Data Involving Transient States: An Illustration Using Heart-Transplant Data (1974) (416)
- Hormone therapy for prostate cancer: results of the Veterans Administration Cooperative Urological Research Group studies. (1989) (358)
- Estrogen treatment for cancer of the prostate. Early results with 3 doses of diethylstilbestrol and placebo (1970) (227)
- Why data bases should not replace randomized clinical trials. (1980) (196)
- Dietary fat reduction and plasma estradiol concentration in healthy postmenopausal women. The Women's Health Trial Study Group. (1990) (192)
- Comparisons of placebo, pyridoxine, and topical thiotepa in preventing recurrence of stage I bladder cancer. (1977) (185)
- Using observational data from registries to compare treatments: the fallacy of omnimetrics. (1984) (154)
- The Veterans Administration Study of Chemoprophylaxis for Recurrent Stage I Bladder Tumours: Comparisons of Placebo, Pyridoxine and Topical Thiotepa (1980) (154)
- Incidence of cardiovascular disease and death in patients receiving diethylstilbestrol for carcinoma of the prostate (1970) (147)
- Design considerations for AIDS trials. (1990) (134)
- Aspects of statistical design for the Community Intervention Trial for Smoking Cessation (COMMIT). (1992) (129)
- Ethics and statistics in randomized clinical trials. (1991) (126)
- How many controls? (1976) (125)
- Survival of patients with incidentally found microscopic cancer of the prostate: results of a clinical trial of conservative treatment. (1972) (117)
- Orchiectomy for advanced prostatic carcinoma. A reevaluation. (1973) (112)
- Clinical staging for cutaneous T-cell lymphoma. (1984) (112)
- Percentage Points of the Asymptotic Distributions of One and Two Sample K-S Statistics for Truncated or Censored Data (1975) (101)
- Problems with using observational databases to compare treatments. (1991) (99)
- Reconsideration of orchiectomy in the treatment of advanced prostatic carcinoma. (1977) (98)
- Assessing apparent treatment--covariate interactions in randomized clinical trials. (1985) (93)
- Clinical predictivity of transplantable tumor systems in the selection of new drugs for solid tumors: rationale for a three-stage strategy. (1983) (92)
- Relationship between estrogen receptor values and clinical data in predicting the response to endocrine therapy for patients with advanced breast cancer. (1979) (87)
- Factorial designs for randomized clinical trials. (1985) (85)
- A comparison of reflected versus test-based confidence intervals for the median survival time, based on censored data. (1984) (83)
- Selecting optimal treatment in clinical trials using covariate information. (1977) (83)
- Prognostic variables in mycosis fungoides (1981) (81)
- Preliminary studies of histologic prognosis in cancer of the prostate. (1977) (77)
- Passive smoking on commercial airline flights. (1989) (74)
- Comparison of four tests for equality of survival curves in the presence of stratification and censoring (1979) (73)
- Special report on Laetrile: the NCI Laetrile Review. Results of the National Cancer Institute's retrospective Laetrile analysis. (1978) (72)
- A quantitative study of the bias in estimating the treatment effect caused by omitting a balanced covariate in survival models. (1988) (70)
- The dietary fat--breast cancer hypothesis is alive. (1989) (68)
- Tests for homogeneity of effect in an epidemiologic investigation. (1977) (65)
- FACTORS AFFECTING FLOW THROUGH A STENOSED VESSEL. (1964) (62)
- Overadjustment in case-control studies. (1980) (61)
- Statistical design of the Women's Health Trial. (1988) (59)
- Status report of 376 mycosis fungoides patients at 4 years: Mycosis Fungoides Cooperative Group. (1979) (57)
- The effect of stratified randomization on size and power of statistical tests in clinical trials. (1978) (57)
- Prognostic Factors for Malignant Glioma (1983) (56)
- Estrogen dosage and suppression of testosterone levels in patients with prostatic carcinoma. (1973) (54)
- Variance Calculations for Direct Adjusted Survival Curves, with Applications to Testing for No Treatment Effect (1986) (53)
- Tryptophan metabolites, pyridoxine (vitamin B6) and their influence on the recurrence rate of superficial bladder cancer. Results of a prospective, randomised phase III study performed by the EORTC GU Group. EORTC Genito-Urinary Tract Cancer Cooperative Group. (1995) (52)
- An exponential model relating censored survival data and concomitant information for prostatic cancer patients. (1974) (52)
- Cancer of the prostate in men less than 50 years old: an analysis of 51 cases. (1969) (52)
- How dependent causes of death can make risk factors appear protective. (1988) (51)
- Assessing the gain in efficiency due to matching in a community intervention study. (1990) (49)
- Decreased helper T lymphocytes in homosexual men. I. Sexual contact in high-incidence areas for the acquired immunodeficiency syndrome. (1985) (44)
- Testing for interaction in an I×J×K contingency table (1977) (40)
- Estrogen predisposes to cholecystectomy but not to stones. (1982) (40)
- Decreased helper T lymphocytes in homosexual men. II. Sexual practices. (1985) (39)
- Testing hypotheses in case-control studies--equivalence of Mantel-Haenszel statistics and logit score tests. (1979) (38)
- Chapter 6 – Zinc in Male Sex Accessory Organs: Distribution and Hormonal Response (1974) (36)
- THE FALLACY OF APPLYING THE POISEUILLE EQUATION TO SEGMENTAL ARTERIAL STENOSIS. (1965) (34)
- The choice of treatment for cancer patients based on covariate information. (1980) (34)
- Marginal homogeneity, symmetry, and independence (1978) (33)
- Results of a clinical trial of surgery and radiation in stages II and 3 carcinoma of the bladder. (1972) (31)
- Incomplete factorial designs for randomized clinical trials. (1993) (30)
- Analysis of the costs of a large prevention trial. (1990) (29)
- An analysis of the effects of changes from the assigned treatment in a clinical trial of treatment for prostatic cancer. (1973) (28)
- Using permutation tests and bootstrap confidence limits to analyze repeated events data from clinical trials. (1989) (26)
- Carcinoma of prostate. Correlation between radiologic quantitation of metastases and patient survival. (1975) (25)
- Dependent competing risks and the latent-failure model. (1988) (24)
- Factorial and reciprocal control designs. (1990) (24)
- Clinical trials in diet and cancer. (1989) (23)
- Quantitative radiology for staging and prognosis of patients with advanced prostatic carcinoma. Correlations with other pretreatment characteristics. (1979) (22)
- Statistical analysis techniques and sample size determination for clinical trials of treatments for bladder cancer. (1986) (20)
- A proposal for registering clinical trials. (1988) (20)
- VACURG randomised trial of radical prostatectomy for stages I and II prostatic cancer. Veterans Administration Cooperative Urological Research Group. (1981) (18)
- Comparison of treatments for prostatic cancer using an exponential-type life model relating survival to concomitant information. (1974) (17)
- Applications of the Mantel-Haenszel statistic to the comparison of survival distributions. (1977) (17)
- Treatment of prostatic cancer: studies by the Veterans Administration cooperative urological research group. (1972) (16)
- The design of cancer prevention trials. (1988) (15)
- Review of the Veterans Administration Studies of Cancer of the Prostate and New Results Concerning Treatment of Stage I and II Tumours (1980) (15)
- Some interrelationships among the regression coefficient estimates arising in a class of models appropriate to response-time data. (1975) (14)
- VACURG studies of conservative treatment. (1980) (14)
- The study of markers of biological effect in cancer prevention research trials (1992) (14)
- Introduction. Errors‐in‐variables workshop (1989) (13)
- Response of serum haptoglobin to hormone treatment and the relation of pretreatment values to mortality in patients with prostatic cancer (1978) (13)
- Clinical predictivity of transplantable tumor systems in the selection of new drugs for solid tumors: reply to a commentary. (1985) (12)
- Results of a E.O.R.T.C. Randomized trial of cyclophosphamide and radiotherapy in inoperable lung cancer: prognostic factors and treatment results. (1978) (12)
- Correlation of pretreatment serum nonprotein-bound cortisol and total 17-hydroxycorticosteroid values with survival in patients with prostatic cancer. (1974) (11)
- Does reserpine increase prolactin and exacerbate cancer of prostate? Case control study. (1973) (11)
- Tryptophan Metabolites, Pyridoxine (Vitamin B(6)) and Their Influence on the Recurrence Rate of Superficial Bladder Cancer (1995) (10)
- BENIGN PROSTATIC HYPERPLASIA AND CANCER OF THE PROSTATE (1975) (10)
- Some statistical considerations for design of cancer prevention trials. (1989) (10)
- The distribution of 65zinc in the prostate and other organs in control, castrated, and hypophysectomized rats. (1969) (9)
- The use of data bases and historical controls in treatment comparisons. (1988) (9)
- Correlation of pre-treatment serum 17-hydroxycorticosteroid values with survival in patients with prostatic cancer. (1975) (8)
- Screening geographic areas for unusual survival experience or stage at diagnosis with application to breast and colon cancer. (1985) (8)
- Possibilities and Limitations of Observational Studies and Evaluation of Medical Data Bases (1981) (7)
- VACURG studies of post-prostatectomy survival. (1980) (6)
- 46. Prognostic Variables for Survival in a Randomized Comparison of Treatments for Prostatic Cancer (1985) (6)
- Discussion of papers on ‘historical and methodological developments in clinical trials at the national institutes of health’ (1990) (6)
- The importance and nature of cancer prevention trials. (1990) (5)
- [Ethics and Statistics in Randomized Clinical Trials]: Comment (1991) (4)
- Sound advice for conducting clinical trials. (1977) (3)
- Design considerations for AIDS trials. (1990) (3)
- Grading prostate cancers. (1983) (3)
- The dietary fat-breast cancer hypothesis: is it really alive? Reply (1990) (3)
- Superiority of PCNU over AZQ in the treatment of primary brain tumors: results of a prospective randomized trial (81-20) by the brain tumor study group (2005) (3)
- Identifying Which Sets of Parameters are Simultaneously Estimable in an Incomplete Factorial Design (1995) (3)
- Reserpine and prostatic cancer (1975) (3)
- Studies of Acid Phosphatase in Prostatic Cancer (1983) (3)
- Predicting survival in terminal cancer. (1973) (3)
- 45. Multiple Tumour Recurrence Data for Patients with Bladder Cancer (1985) (3)
- Incidence, mortality, and survival statistics for prostatic cancer. (1987) (2)
- Quantification of the effects of preventive measures. (1990) (2)
- Correlation Between Radiologic Quantitation of Metastases and Patient Survival (1975) (2)
- Errors-in-variables workshop. (1989) (2)
- A computerized reference laboratory. (1979) (1)
- Partial factorial designs for randomized clinical trials (1985) (1)
- Passive Smoking on Commercial Airlines-Reply (1989) (1)
- Using case-control data to estimate sample sizes required for disease prevention trials in high-risk groups (1984) (1)
- Guidelines for Reporting Studies of Treatment for Prostatic Cancer (1988) (1)
- Proper analysis of clinical trials for malignant glioma. (1981) (1)
- Results of clinical trials of estrogen treatment (1973) (1)
- Projecting breast cancer probabilities. Comments. Authors' reply (1990) (0)
- Play‐The‐Winner Rules (2006) (0)
- Design of Prevention Trials (2021) (0)
- [Use of prognostic knowledge in the planning and analysis of randomized therapeutic trials]. (1987) (0)
- Letters: Rserpine and prostatic cancer. (1975) (0)
- A quantitative study of the missing covariate bias in survival studies (1985) (0)
- Factorial designs for randomized trials (1984) (0)
- Comparing treatments in subsets of patients (1981) (0)
- AbstractDirect adjusted survival curves for comparing two treatments (1981) (0)
- Pulmonary and Osseous Metastases in Prostatic Cancer: Methods of Quantitative Assessment (1983) (0)
- 9. The fallacy of applying the poiseuille equation to segmental arterial stenosis (1965) (0)
- Analysis of cancer patient survival with the weibull model (1981) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With David P. Byar?
David P. Byar is affiliated with the following schools:
